In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 26, No. 4 ( 2006-04), p. 845-850
Abstract:
The present randomized, placebo-controlled, single-blind trial demonstrates in nondiabetic patients scheduled for carotid endarterectomy that 4 weeks of treatment with rosiglitazone significantly reduces vascular inflammation, leading to a more stable type of arteriosclerotic lesion.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/01.ATV.0000203511.66681.7f
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2006
detail.hit.zdb_id:
1494427-3
Permalink